Inflammopharmacology

FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?

• Research Article

Garry G. Graham, Richard O. Day, Andis Graudins, Anthoulla Mohamudally

Erratum to: FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?

• Erratum

Garry G. Graham, Richard O. Day, Andis Graudins, Anthoulla Mohamudally

Relevance of Helicobacter pylori genotypes in gastric pathology and its association with plasma malondialdehyde and nitric oxide levels

• Research Article

Santosh K. Tiwari, G. Manoj, Vishwas Sharma, G. Sivaram, R. Saikant, Avinash Bardia, Varun K. Sharma, Zakia Abid, Aleem A. Khan, M. Aejaz Habeeb, C. M. Habibullah, B. Santhosh Kumar, Amrita Nandan

Synergism between COX-3 inhibitors in two animal models of pain

• Research Article

J. Muñoz, C. Navarro, V. Noriega, G. Pinardi, F. Sierralta, J. C. Prieto, H. F. Miranda

Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease

• Research Article

Lynn W. Maines, Leo R. Fitzpatrick, Cecelia L. Green, Yan Zhuang, Charles D. Smith

Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats

• Research Article

Omar Mohamed E. Abdel Salam, Amany A. Sleem, Nermeen Shafee

Hungarian Experimental and Clinical Pharmacology Society Abstracts

• Abstracts